Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
protease inhibitor |
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:FDA
1994 |
| gptkbp:ATCCode |
J05AF04
|
| gptkbp:brand |
gptkb:Zerit
|
| gptkbp:CASNumber |
3056-17-5
|
| gptkbp:chemicalClass |
gptkb:stavudine
|
| gptkbp:contraindication |
gptkb:liver_disease
pregnancy |
| gptkbp:discoveredBy |
gptkb:Yale_University
|
| gptkbp:discoveredIn |
1966
|
| gptkbp:eliminationHalfLife |
1 hour
|
| gptkbp:hasMolecularFormula |
C10H12N2O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
d4T
|
| gptkbp:isOnWHOList |
gptkb:Essential_Medicines
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:sideEffect |
pancreatitis
peripheral neuropathy lactic acidosis |
| gptkbp:synonym |
2',3'-didehydro-3'-deoxythymidine
Didehydrodeoxythymidine |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:stavudine
|
| gptkbp:bfsLayer |
6
|